10-Q
Quarterly Report
10x Genomics, Inc.
TXG
NASDAQ
CIK: 1770787
File #: 001-39035
Balance Sheet
44 line items · 2 periods
XBRL
| Item | Sep 30, 2025 | Dec 31, 2024 |
|---|---|---|
Assets | ||
Current assets: | ||
Cash and cash equivalents | 432,508,000 | 344,067,000 |
Marketable securities | 49,576,000 | 49,335,000 |
Accounts receivable, net | 43,779,000 | 87,862,000 |
Other receivables | 52,813,000 | 606,000 |
Inventory | 61,956,000 | 83,107,000 |
Prepaid expenses and other current assets | 19,195,000 | 19,410,000 |
Total current assets | 659,827,000 | 584,387,000 |
Property and equipment, net | 232,534,000 | 252,648,000 |
Restricted cash | 201,000 | 0 |
Operating lease right-of-use assets | 63,650,000 | 57,290,000 |
Scale BioScience Inc. Acquisition | 1,800,000 | — |
Goodwill | 4,511,000 | 4,511,000 |
Intangible assets, net | 64,759,000 | 15,671,000 |
Other noncurrent assets | 1,879,000 | 4,129,000 |
Total assets | 1,027,361,000 | 918,636,000 |
Liabilities and stockholders’ equity | ||
Current liabilities: | ||
Accounts payable | 18,069,000 | 12,909,000 |
Accrued compensation and related benefits | 37,084,000 | 33,615,000 |
Accrued expenses and other current liabilities | 35,766,000 | 41,165,000 |
Deferred revenue | 22,139,000 | 20,658,000 |
Products and Services, Excluding Grant Revenue | 22,100,000 | — |
Operating lease liabilities | 10,543,000 | 9,286,000 |
Contingent consideration, current | 23,723,000 | 0 |
Total current liabilities | 147,324,000 | 117,633,000 |
Contingent consideration, noncurrent | 1,210,000 | 0 |
Operating lease liabilities, noncurrent | 76,442,000 | 73,327,000 |
Deferred revenue, noncurrent | 10,871,000 | 12,513,000 |
Other noncurrent liabilities | 6,394,000 | 5,029,000 |
Total liabilities | 242,241,000 | 208,502,000 |
Stockholders’ equity: | ||
Preferred stock | 0 | 0 |
Common stock | 2,000 | 2,000 |
Additional paid-in capital | 2,279,319,000 | 2,177,672,000 |
Accumulated deficit | (1,494,339,000) | (1,467,047,000) |
Accumulated other comprehensive income (loss) | 138,000 | (493,000) |
Total stockholders’ equity | 785,120,000 | 710,134,000 |
Common Stock | 2,000 | 2,000 |
Additional Paid-in Capital | 2,279,319,000 | 2,177,672,000 |
Accumulated Deficit | (1,494,339,000) | (1,467,047,000) |
Accumulated Other Comprehensive Income (Loss) | 138,000 | (493,000) |
Total liabilities and stockholders’ equity | 1,027,361,000 | 918,636,000 |